Alnylam Pharmaceuticals EBIT 2010-2024 | ALNY

Alnylam Pharmaceuticals EBIT for the quarter ending September 30, 2024 was $-0.077B, a 135.96% decline year-over-year.

  • Alnylam Pharmaceuticals 2023 EBIT was -0.282B, a 64.06% decline from 2022.
  • Alnylam Pharmaceuticals 2022 EBIT was -0.785B, a 10.78% increase from 2021.
  • Alnylam Pharmaceuticals 2021 EBIT was -0.709B, a 14.46% decline from 2020.

EBIT can be defined as earnings before interest and taxes.

Alnylam Pharmaceuticals EBIT 2010-2024 | ALNY

  • Alnylam Pharmaceuticals 2023 EBIT was -0.282B, a 64.06% decline from 2022.
  • Alnylam Pharmaceuticals 2022 EBIT was -0.785B, a 10.78% increase from 2021.
  • Alnylam Pharmaceuticals 2021 EBIT was -0.709B, a 14.46% decline from 2020.

EBIT can be defined as earnings before interest and taxes.